secwatch.observer — SEC 8-K summary
======================================

Issuer:     Connect Biopharma Holdings Ltd (CNTB)
CIK:        0001835268
Form:       8-K
Filed at:   2026-09-30T11:05:05+00:00
Accession:  0001835268-26-000038
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Connect Biopharma's rademikibart cuts COPD treatment failure 81% in Phase 2; plans FDA Phase 3 talks
--------------------------------------------------------------------------------

- Phase 2 Seabreeze STAT (CBP-201-207) enrolled 159 COPD patients with eosinophils >=300 cells/uL; randomized 1:1 to single subcutaneous rademikibart or placebo plus standard of care.
- Treatment failure rate fell 81% through Week 4 vs placebo (p=0.0122); new moderate-to-severe COPD exacerbations fell 85% (p=0.030).
- ED visits and hospital admissions for new exacerbations reduced 100% (p=0.0137); rescue inhaler use cut from Week 2-7 with symptom improvement at Week 2 (p=0.0197).
- FEV1 improved 70 mL at Week 4 vs placebo but missed significance (p=0.1607); rademikibart well tolerated with lower adverse and serious adverse event rates than placebo.
- CEO Barry Quart cited 2025 claims data showing ~$6B in 30-day COPD ED return-visit costs; Connect plans to engage FDA on a Phase 3 registrational program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835268/000183526826000038/0001835268-26-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835268/000183526826000038/cntb-20260930.htm
  HTML page:      https://secwatch.observer/filing/0001835268-26-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer